The present disclosure is directed to capsid assembly inhibitor compositions and methods for use in the treatment of hepatitis B virus infection.

The present invention relates to a composition and a combination comprising at least one first drug and at least one protein-binding prodrug, wherein the protein-binding prodrug comprises a protein-binding group, a second drug, and a linker that can be cleaved hydrolytically, enzymatically, or in a pH-dependent manner in the body, as well as to a kit and a pharmaceutical composition comprising said composition or combination.

The present disclosure provides pyrrolopyrimidine nucleoside analogs of the Formula I, Formula IA, Formula IB, or Formula II and phospholipid conjugates and pharmaceutical compositions thereof wherein R.sub.c and A are defined herein. Also presented are methods of treating and/or preventing viral infection and/or viral infection-associated disease or disorder with one or more compounds of Formula I, Formula IA, Formula IB, or Formula II. ##STR00001##

The present invention provides a novel phillygenin glucuronic acid derivative shown as a general formula (I). ##STR00001##
wherein, R.sub.1=H, R.sub.2=C.sub.nH.sub.2n+1, R.sub.3=C.sub.nH.sub.2n+1 or R.sub.1=C.sub.nH.sub.2n+1, R.sub.2=C.sub.nH.sub.2n+1,R.sub.3=H or R.sub.1-R.sub.2=CH.sub.2, R.sub.3=C.sub.nH.sub.2n+1; n=1-30. The present invention further relates to a preparation method of the compound, a pharmaceutical composition taking the compound as an active ingredient, as well as application of the compound in the present invention in antiviral diseases.

Phosphoramidate derivatives of nucleotides and their use in the treatment of cancer are described. The base moieties of, for example, each of deoxyuridine, cytarabine, gemcitabine and citidine may be substituted at the 5-position. The phosphoramidate moiety has attached to the P atom an aryl-O moiety and an -amino acid moiety. The -amino acid moiety may correspond to or be derived from either a naturally occurring or a non-naturally occurring amino acid.

The invention relates to medicine, hepatology and pharmacology and can be used for producing and using a pharmaceutical composition based on a hepatoprotector and a prebiotic for treating and preventing liver diseases which are caused by lipid-cholesterol exchange and selected from the following group: cholelitiasis mainly with cholesterol stones, alcoholic and non-alcoholic steatohepatitis, biliary cirrhosis, cholesterol imbibition gallbladder and drug-induced and toxic liver damage. The pharmaceutical composition is administered by mouth and contains a hepatoprotector and a prebiotic taken, as an active agent, in therapeutically effective doses. The invention contributes to the liver's functional recovery in a short time and prevents disease recidivation owing to the recovery of cholesterol exchange and intestinal biocenosis as a result of the synergistic interaction of a hepatoprotector and a prebiotic, thereby also preventing hepatoprotector side effects.

The present disclosure provides pyrrolopyrimidine nucleoside analogs of the Formula I, Formula IA, Formula IB, or Formula II and phospholipid conjugates and pharmaceutical compositions thereof wherein R.sub.c and A are defined herein. Also presented are methods of treating and/or preventing viral infection and/or viral infection-associated disease or disorder with one or more compounds of Formula I, Formula IA, Formula IB, or Formula II. ##STR00001##

A composition can treat or prevent at least one physical state selected from the group consisting of oxidative stress, a condition associated with oxidative stress, a reduced level of glutathione, and a condition associated with a reduced level of glutathione. The composition contains an effective amount of a combination of at least one glycine or functional derivative thereof, at least one N-acetylcysteine or functional derivative thereof, and at least one nicotinamide riboside or NAD.sup.+ precursor. The composition can be orally administered, for example as one or more of a food product, a food for special medical purposes (FSMP), a nutritional supplement, a ready to drink formula, a dairy-based drink, a low-volume liquid supplement, powder formats for liquid reconstitution or a meal replacement beverage.

Disclosed are analogs of adenosine monophosphate (AMP) as inhibitors of ubiquitin-like modifier-activing enzyme ATG7. The AMP analogs may be formulated as pharmaceutical compositions for treating diseases or disorders that depend on ATG7 activity and/or autophagy such as cell proliferative diseases and disorders.

The present invention provides therapeutic agents for preventing and treating neurodegenerative diseases. These agents synergistically target both the adenosine A.sub.2A receptor (A.sub.2AR) and the equilibrative nucleoside transporter 1 (ENT1).